Assignee
SEAGEN INC
US·57 granted patents·127 pending applications·79 citations·filing 2011–2025
Top patents by PatentIndex Score
184 records- 0196US11077164B2Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugatesSEAGEN INC·Filed 2021·Granted Aug 3, 2021·3 cites·18 claims
- 0296US10940178B2Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugatesSEAGEN INC·Filed 2020·Granted Mar 9, 2021·4 cites·30 claims
- 0395US11510959B2Hydrophilic antibody-drug conjugatesSEAGEN INC·Filed 2021·Granted Nov 29, 2022·3 cites·11 claims
- 0495US11369658B2Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugatesSEAGEN INC·Filed 2021·Granted Jun 28, 2022·2 cites·9 claims
- 0595US11078291B2BCMA antibodies and use of same to treat cancer and immunological disordersSEAGEN INC·Filed 2019·Granted Aug 3, 2021·8 cites·66 claims
- 0695US10912813B2Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugatesSEAGEN INC·Filed 2018·Granted Feb 9, 2021·5 cites·1 claims
- 0792US10933112B2Hydrophilic antibody-drug conjugatesSEAGEN INC·Filed 2015·Granted Mar 2, 2021·5 cites·24 claims
- 0891US2024415917A1Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugatesSEAGEN INC·Filed 2024·Application pending·0 cites
- 0989US11767365B2BCMA antibodies and use of same to treat cancer and immunological disordersSEAGEN INC·Filed 2021·Granted Sep 26, 2023·1 cites·73 claims
- 1089US11666572B2Treatment of HER2 positive cancersSEAGEN INC·Filed 2021·Granted Jun 6, 2023·2 cites·23 claims
- 1189US11207324B2Treatment of HER2 positive cancersSEAGEN INC·Filed 2018·Granted Dec 28, 2021·6 cites·53 claims
- 1288US12036286B2Selective drug release from internalized conjugates of biologically active compoundsSEAGEN INC·Filed 2022·Granted Jul 16, 2024·2 cites·12 claims
- 1388US11319526B2Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylationSEAGEN INC·Filed 2019·Granted May 3, 2022·2 cites·63 claims
- 1488US2024252672A1Beta-glucuronide-linker drug conjugatesSEAGEN INC·Filed 2023·Application pending·0 cites
- 1586US11103593B2Pegylated drug-linkers for improved ligand-drug conjugate pharmacokineticsSEAGEN INC·Filed 2014·Granted Aug 31, 2021·13 cites·26 claims
- 1686US2024190981A1Humanized Anti-CD70 Binding Agents and Uses ThereofSEAGEN INC·Filed 2023·Application pending·0 cites
- 1785USRE48959EHumanized antibodies to LIV-1 and use of same to treat cancerSEAGEN INC·Filed 2011·Granted Mar 8, 2022·4 cites·124 claims
- 1885US2024139275A1Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugatesSEAGEN INC·Filed 2022·Application pending·0 cites
- 1984US12257281B2Hydrophilic antibody-drug conjugatesSEAGEN INC·Filed 2023·Granted Mar 25, 2025·0 cites·6 claims
- 2084US11559558B2Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugatesSEAGEN INC·Filed 2022·Granted Jan 24, 2023·0 cites·30 claims
- 2184US2024247059A1Humanized antibodies to liv-1 and use of same to treat cancerSEAGEN INC·Filed 2023·Application pending·0 cites
- 2284US2024109975A1Bcma antibodies and use of same to treat cancer and immunological disordersSEAGEN INC·Filed 2023·Application pending·0 cites
- 2383US12496353B2Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathwaySEAGEN INC·Filed 2023·Granted Dec 16, 2025·0 cites·13 claims
- 2483US11116847B2Methylene carbamate linkers for use with targeted-drug conjugatesSEAGEN INC·Filed 2014·Granted Sep 14, 2021·3 cites·53 claims
- 2583US11028181B2Glycan-interacting compounds and methods of useSEAGEN INC·Filed 2016·Granted Jun 8, 2021·3 cites·93 claims
- 2682US11202827B2Dosage and administration of non-fucosylated anti-CD40 antibodiesSEAGEN INC·Filed 2017·Granted Dec 21, 2021·2 cites·170 claims
- 2781US11844839B2Process for the preparation of pegylated drug-linkers and intermediates thereofSEAGEN INC·Filed 2017·Granted Dec 19, 2023·2 cites·26 claims
- 2881US2024084031A1Variant target binding agents and uses thereofSEAGEN INC·Filed 2022·Application pending·0 cites
- 2981US2024075134A1Dosage and administration of non-fucosylated anti-cd40 antibodySEAGEN INC·Filed 2023·Application pending·0 cites
- 3081US2023242648A1Antibodies to integrin avb6 and use of same to treat cancerSEAGEN INC·Filed 2023·Application pending·0 cites
- 3180US2024075135A1Dosage and administration of non-fucosylated anti-cd40 antibodiesSEAGEN INC·Filed 2023·Application pending·0 cites
- 3280US2023055475A1Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylationSEAGEN INC·Filed 2022·Application pending·0 cites
- 3379US11541128B2Multi-drug antibody drug conjugatesSEAGEN INC·Filed 2017·Granted Jan 3, 2023·2 cites·15 claims
- 3479US2023201344A1Dosage and administration of non-fucosylated anti-cd40 antibodySEAGEN INC·Filed 2022·Application pending·0 cites
- 3579US2023033859A1Cd19 binding agents and uses thereofSEAGEN INC·Filed 2022·Application pending·0 cites
- 3678US2023201343A1Dosage and administration of non-fucosylated anti-cd40 antibodiesSEAGEN INC·Filed 2022·Application pending·0 cites
- 3778US2022143209A1Beta-glucuronide-linker drug conjugatesSEAGEN INC·Filed 2021·Application pending·0 cites
- 3878US2023132738A1Hydrophilic antibody-drug conjugatesSEAGEN INC·Filed 2022·Application pending·0 cites
- 3978US2023105802A1Anti-ntb-a antibodies and related compositions and methodsSEAGEN INC·Filed 2022·Application pending·0 cites
- 4078US2022265822A1Dosage and administration of non-fucosylated anti-cd40 antibodySEAGEN INC·Filed 2022·Application pending·0 cites
- 4177US12048698B2Treatment of HER2 positive cancersSEAGEN INC·Filed 2023·Granted Jul 30, 2024·0 cites·19 claims
- 4277US11819553B2Glypican 3 antibodies and conjugates thereofSEAGEN INC·Filed 2019·Granted Nov 21, 2023·1 cites·21 claims
- 4377US11730822B2Process for the preparation of glucuronide drug-linkers and intermediates thereofSEAGEN INC·Filed 2018·Granted Aug 22, 2023·1 cites·48 claims
- 4477US2024325561A1Pegylated drug-linkers for improved ligand-drug conjugate pharmacokineticsSEAGEN INC·Filed 2024·Application pending·0 cites
- 4577US2022249662A1Dosage and administration of non-fucosylated anti-cd40 antibodiesSEAGEN INC·Filed 2022·Application pending·0 cites
- 4676US11401339B2Anti-TIGIT antibodiesSEAGEN INC·Filed 2019·Granted Aug 2, 2022·1 cites·122 claims
- 4776US11033561B2Methods of inhibition of protein fucosylation in vivo using fucose analogsSEAGEN INC·Filed 2019·Granted Jun 15, 2021·0 cites·17 claims
- 4876US2023391848A1Selective reduction of proteinsSEAGEN INC·Filed 2023·Application pending·0 cites
- 4976US2024343826A1Compositions and Methods for Targeting Cancer Stem CellsSEAGEN INC·Filed 2023·Application pending·0 cites
- 5075US12268751B2Anti-αVβ6 antibodies and antibody-drug conjugatesSEAGEN INC·Filed 2023·Granted Apr 8, 2025·0 cites·15 claims
Showing the top 50 of 184 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when SEAGEN INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →